Citations (94)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Vincenzo De Sanctis, Ashraf T Soliman, Heba Elsedfy, Alessia Pepe, Christos Kattamis, Mohamed El Kholy & Mohamed Yassin. (2016) Diabetes and Glucose Metabolism in Thalassemia Major: An Update. Expert Review of Hematology 9:4, pages 401-408.
Read now
Read now
Jung H. Suh, Régis Moreau, Shi-Hua D. Heath & Tory M. Hagen. (2005) Dietary supplementation with (R)-α-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Report 10:1, pages 52-60.
Read now
Read now
Mary Ann Howland. (1996) Risks of Parenteral Deferoxamine for Acute Iron Poisoning. Journal of Toxicology: Clinical Toxicology 34:5, pages 491-497.
Read now
Read now
Mark M. Jones. (1991) New Developments in Therapeutic Chelating Agents as Antidotes for Metal Poisoning. Critical Reviews in Toxicology 21:3, pages 209-233.
Read now
Read now
Articles from other publishers (90)
Subhangi Basu, Motiur Rahaman, Tuphan Kanti Dolai, Praphulla Chandra Shukla & Nishant Chakravorty. (2023) Understanding the Intricacies of Iron Overload Associated with β-Thalassemia: A Comprehensive Review. Thalassemia Reports 13:3, pages 179-194.
Crossref
Crossref
Ying Chen, Xiaoming Liao, Pei Jing, Liangkui Hu, Zengqiu Yang, Yongchao Yao, Chunyan Liao & Shiyong Zhang. (2022) Linoleic Acid–Glucosamine Hybrid for Endogenous Iron-Activated Ferroptosis Therapy in High-Grade Serous Ovarian Cancer. Molecular Pharmaceutics 19:9, pages 3187-3198.
Crossref
Crossref
Douglas B. Kell & Etheresia Pretorius. (2022) The potential role of ischaemia–reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochemical Journal 479:16, pages 1653-1708.
Crossref
Crossref
Cristina Fernández-Mendívil, Enrique Luengo, Paula Trigo-Alonso, Nuria García-Magro, Pilar Negredo & Manuela G. López. (2021) Protective role of microglial HO-1 blockade in aging: Implication of iron metabolism. Redox Biology 38, pages 101789.
Crossref
Crossref
Jan Mach & Robert Sutak. (2020) Iron in parasitic protists – from uptake to storage and where we can interfere. Metallomics 12:9, pages 1335-1347.
Crossref
Crossref
John Chapin & Patricia J. Giardina. 2018. Hematology. Hematology
546
570.e10
.
Ayfer Gözü Pirinççioğlu. (2017) Parathyroid Functions in Thalassemia Major Patients. Annals of Clinical Endocrinology and Metabolism 1:1, pages 015-019.
Crossref
Crossref
Umar Saeed & Zahra Zahid Piracha. (2016) Thalassemia: Impact of consanguineous marriages on most prevalent monogenic disorders of humans. Asian Pacific Journal of Tropical Disease 6:10, pages 837-840.
Crossref
Crossref
Farid A. Badria, Ahmed S. Ibrahim, Adel F. Badria & Ahmed A. Elmarakby. (2015) Curcumin Attenuates Iron Accumulation and Oxidative Stress in the Liver and Spleen of Chronic Iron-Overloaded Rats. PLOS ONE 10:7, pages e0134156.
Crossref
Crossref
Jean-Antoine Ribeil, Jean-Benoit Arlet, Michael Dussiot, Ivan Cruz Moura, Geneviève Courtois & Olivier Hermine. (2013)
Ineffective Erythropoiesis in
β
-Thalassemia
. The Scientific World Journal 2013, pages 1-11.
Crossref
Crossref
Leah R. Hanson, Jared M. Fine, Dan B. Renner, Aleta L. Svitak, Rachel B. Burns, Thuhien M. Nguyen, Nathan J. Tuttle, Dianne L. Marti, S. Scott Panter & William H. FreyIIII. (2012) Intranasal delivery of deferoxamine reduces spatial memory loss in APP/PS1 mice. Drug Delivery and Translational Research 2:3, pages 160-168.
Crossref
Crossref
John B. Porter & Chaim Hershko. 2012. Iron Physiology and Pathophysiology in Humans. Iron Physiology and Pathophysiology in Humans
591
627
.
Samir M. Awadallah, Nisreen A. Nimer, Manar F. Atoum & Suleiman A. Saleh. (2011) Association of haptoglobin phenotypes with ceruloplasmin ferroxidase activity in β-thalassemia major. Clinica Chimica Acta 412:11-12, pages 975-979.
Crossref
Crossref
A Tabak, E Hoffer & U Taitelman. (1994) Evaluation of a Liposome System for the Delivery of Desferrioxamine to Lungs in Rats. Journal of Pharmacy and Pharmacology 46:10, pages 789-796.
Crossref
Crossref
Douglas B. Kell. (2010) Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples. Archives of Toxicology 84:11, pages 825-889.
Crossref
Crossref
Chaim Hershko. (2010) Pathogenesis and management of iron toxicity in thalassemia. Annals of the New York Academy of Sciences 1202:1, pages 1-9.
Crossref
Crossref
Magdy Selim. (2009) Treatment with the Iron Chelator, Deferoxamine Mesylate, Alters Serum Markers of Oxidative Stress in Stroke Patients. Translational Stroke Research 1:1, pages 35-39.
Crossref
Crossref
Douglas B Kell. (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Medical Genomics 2:1.
Crossref
Crossref
Brandon Wayne Alderman, Amy E. Ratliff & Joseph Ivan Wirgau. (2009) A mechanistic study of ferrioxamine B reduction by the biological reducing agent ascorbate in the presence of an iron(II) chelator. Inorganica Chimica Acta 362:6, pages 1787-1792.
Crossref
Crossref
Antonio Piga, Filomena Longo, Lorena Duca, Simona Roggero, Tiziana Vinciguerra, Roberto Calabrese, Chaim Hershko & Maria Domenica Cappellini. (2008) High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology 84:1, pages 29-33.
Crossref
Crossref
Sophie Vaulont & Dominique Labie. (2008) GDF15 coupable de l’hypersidérémie des patients thalassémiques par extinction de l’hepcidine. médecine/sciences 24:2, pages 139-141.
Crossref
Crossref
Paulina Karhumäki, Sari L. Tiitinen, Hannu Turpeinen & Jaakko Parkkinen. (2007) Inhibition of ERK1/2 Activation by Phenolic Antioxidants Protects Kidney Tubular Cells During Cold Storage. Transplantation 83:7, pages 948-953.
Crossref
Crossref
Jin Won HuhYangjin JegalSang-Bum HongYeon Mok OhTae Sun ShimChae-Man LimSang Do LeeWoo Sung KimDong Soon KimWon Dong KimYounsuck Koh. (2007) Efficacy of deferoxamine on paraquat poisoning. Tuberculosis and Respiratory Diseases 62:2, pages 113.
Crossref
Crossref
Hava GlicksteinRinat Ben ElGabi LinkWilliam BreuerAbraham M. KonijnChaim HershkoHanspeter NickZ. Ioav Cabantchik. (2006) Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108:9, pages 3195-3203.
Crossref
Crossref
Xi-Ping Huang, Peter J. O’Brien & Douglas M. Templeton. (2006) Mitochondrial involvement in genetically determined transition metal toxicity. Chemico-Biological Interactions 163:1-2, pages 68-76.
Crossref
Crossref
Jacob Golenser, Abraham Domb, Talya Mordechai-Daniel, Benny Leshem, Adrian Luty & Peter Kremsner. (2006) IRON CHELATORS: CORRELATION BETWEEN EFFECTS ON PLASMODIUM SPP. AND IMMUNE FUNCTIONS. Journal of Parasitology 92:1, pages 170-177.
Crossref
Crossref
C.AIM HERSHKO, GABRIELA LINK, ABRAHAM M. KONIJN & Z IOAV CABANTCHIK. (2009) Objectives and Mechanism of Iron Chelation Therapy. Annals of the New York Academy of Sciences 1054:1, pages 124-135.
Crossref
Crossref
M Sauer, C Bettoni, M Lauten, A Ghosh, K Rehe, L Grigull, A Beilken, K Welte & K W Sykora. (2005) Complete substitution of cyclophosphamide by fludarabine and ATG in a busulfan-based preparative regimen for children and adolescents with β-thalassemia. Bone Marrow Transplantation 36:5, pages 383-387.
Crossref
Crossref
A. Taher. (2005) Iron overload in thalassemia and sickle cell disease. Seminars in Hematology 42:2, pages S5-S9.
Crossref
Crossref
Chaim Hershko, Maria D Cappellini, Renzo Galanello, Antonio Piga, Gianni Tognoni & Giuseppe Masera. (2004) Purging iron from the heart. British Journal of Haematology 125:5, pages 545-551.
Crossref
Crossref
Guido Lucarelli & Reginald A. Clift. 2003. Thomas' Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation
1407
1416
.
Raymond J Bergeron, Guangfei Huang, Richard E Smith, Neelam Bharti, James S McManis & Alison Butler. (2003) Total synthesis and structure revision of petrobactin. Tetrahedron 59:11, pages 2007-2014.
Crossref
Crossref
Donald J. AbrahamRaymond J. Bergeron, James S. McManis, William R. Weimar, Jan Wiegand & Eileen Eiler‐McManis. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
480
561
.
Louise Lo & Sylvia Titi Singer. (2002) Thalassemia: current approach to an old disease. Pediatric Clinics of North America 49:6, pages 1165-1191.
Crossref
Crossref
Alison Jones & Robert Flanagan. 2001. Antidotes. Antidotes
35
93
.
D.J. Weatherall & J.B. Clegg. 2001. The Thalassaemia Syndromes. The Thalassaemia Syndromes
733
821
.
Susanne ReichChristoph BührerGünter HenzeDieter OhlendorfMichael MeschePranav SinhaAndreas KageChristian MüllerBarbara VetterAndreas E. Kulozik. (2000) Oral isobutyramide reduces transfusion requirements in some patients with homozygous β-thalassemia. Blood 96:10, pages 3357-3363.
Crossref
Crossref
Kim Kramer-Stickland, Andrew Edmonds, Warner B. BairIIIIII & G.Tim Bowden. (1999) Inhibitory effects of deferoxamine on UVB-induced AP-1 transactivation. Carcinogenesis 20:11, pages 2137-2142.
Crossref
Crossref
Des R. Richardson. (1999) Role of ceruloplasmin and ascorbate in cellular iron release. Journal of Laboratory and Clinical Medicine 134:5, pages 454-465.
Crossref
Crossref
Nancy F. Olivieri. (1999) The β-Thalassemias. New England Journal of Medicine 341:2, pages 99-109.
Crossref
Crossref
Gabriela Link, Abraham M. Konijn & Chaim Hershko. (1999) Cardioprotective effect of ?-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells. Journal of Laboratory and Clinical Medicine 133:2, pages 179-188.
Crossref
Crossref
Colin G. Steward. 1999. Blood Cell Biochemistry. Blood Cell Biochemistry
13
56
.
J Aubrey Waddell, Lance C Hannan & Marissa R Stephens. (2016) Pharmacy Technician Competencies for Practice in an Oncology Pharmacy. Journal of Pharmacy Technology 14:5, pages 191-201.
Crossref
Crossref
CHAIM HERSHKO, GABRIELA LINK & IOAV CABANTCHIK. (1998) Pathophysiology of Iron Overloada. Annals of the New York Academy of Sciences 850:1 COOLEY'S ANEM, pages 191-201.
Crossref
Crossref
Chaim Hershko, Abraham M. Konijn & Gabriela Link. (2001) Iron Chelators for Thalassaemia. British Journal of Haematology 101:3, pages 399-406.
Crossref
Crossref
Gabriela Link, Ann Saada, Arie Pinson, Abraham M. Konijn & Chaim Hershko. (1998) Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. Journal of Laboratory and Clinical Medicine 131:5, pages 466-474.
Crossref
Crossref
Paul Baret, Virginie Beaujolais, Claude Béguin, Didier Gaude, Jean-Louis Pierre & Guy Serratrice. (1998) Towards New Iron(III) Chelators: Synthesis and Complexing Ability of a Water-Soluble Tripodal Ligand Based on 2,2′-Dihydroxybiphenyl Subunits. European Journal of Inorganic Chemistry 1998:5, pages 613-619.
Crossref
Crossref
D.J. Weatherall. (1998) 4 Pathophysiology of thalassaemia. Baillière's Clinical Haematology 11:1, pages 127-146.
Crossref
Crossref
Elena E Lomonosova, Michael Kirsch, Ursula Rauen & Herbert de Groot. (1998) The Critical Role of Hepes in SIN-1 Cytotoxicity, Peroxynitrite Versus Hydrogen Peroxide. Free Radical Biology and Medicine 24:4, pages 522-528.
Crossref
Crossref
Laura L. Horky, Ryszard M. Pluta, Robert J. Boock & Edward H. Oldfield. (1998) Role of ferrous iron chelator 2,2′-dipyridyl in preventing delayed vasospasm in a primate model of subarachnoid hemorrhage. Journal of Neurosurgery 88:2, pages 298-303.
Crossref
Crossref
G. Zanninelli, H. Glickstein, W. Breuer, P. Milgram, P. Brissot, R. C. Hider, A. M. Konijn, J. Libman, A. Shanzer & Z. Ioav Cabantchik. (1997) Chelation and Mobilization of Cellular Iron by Different Classes of Chelators. Molecular Pharmacology 51:5, pages 842-852.
Crossref
Crossref
Nancy F. OlivieriGary M. Brittenham. (1997) Iron-Chelating Therapy and the Treatment of Thalassemia. Blood 89:3, pages 739-761.
Crossref
Crossref
L. T. Minina, T. M. Prostakova, A. Yu. Meshschanov, G. N. Kol'tsova & V. N. Bovenko. (1996) A comparative study of two models of hemosiderosis used for the investigation of iron chelators. Bulletin of Experimental Biology and Medicine 122:3, pages 965-966.
Crossref
Crossref
William Breuer, Silvina Epsztejn & Z. Ioav Cabantchik. (2001) Dynamics of the cytosolic chelatable iron pool of K562 cells. FEBS Letters 382:3, pages 304-308.
Crossref
Crossref
William Breuer, Silvina Epsztejn & Z. Ioav Cabantchik. (1995) Iron Acquired from Transferrin by K562 Cells Is Delivered into a Cytoplasmic Pool of Chelatable Iron(II). Journal of Biological Chemistry 270:41, pages 24209-24215.
Crossref
Crossref
Manuka Ghosh, Lester J. Lambert, Paul W. Huber & Marvin J. Miller. (1995) Synthesis, bioactivity, and DNA-cleaving ability of desferrioxamine B-nalidixic acid and anthraquinone carboxylic acid conjugates. Bioorganic & Medicinal Chemistry Letters 5:20, pages 2337-2340.
Crossref
Crossref
Dalibor Gergeľ, Vladimír Mišík, Karol Ondriaš & Arthur I. Cederbaum. (1995) Increased Cytotoxicity of 3-Morpholinosydnonimine to HepG2 Cells in the Presence of Superoxide Dismutase. Journal of Biological Chemistry 270:36, pages 20922-20929.
Crossref
Crossref
M ChevionL ChuangJ Golenser. (1995) Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Antimicrobial Agents and Chemotherapy 39:8, pages 1902-1905.
Crossref
Crossref
Joel G. Parkes, Edward W. Randell, Nancy F. Olivieri & Douglas M. Templeton. (1995) Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1243:3, pages 373-380.
Crossref
Crossref
Paolo Cavallo-Perin, Giovanni Pacini, Franco Cerutti, Anna Bessone, Carmen Condo, Laura Sacchetti, Antonio Piga & Gianfranco Pagano. (1995) Insulin resistance and hyperinsulinemia in homozygous ?-thalassemia. Metabolism 44:3, pages 281-286.
Crossref
Crossref
Z.I. Cabantchik. (1995) Iron Chelators as antimalarials: the biochemical basis of selective cytotoxicity. Parasitology Today 11:2, pages 74-78.
Crossref
Crossref
Peter H. Evans. 1995. Immunopharmacology of Free Radical Species. Immunopharmacology of Free Radical Species
247
262
.
D. M. Templeton. 1995. Toxicology of Metals. Toxicology of Metals
305
331
.
Chaim Hershko. (1994) 11 Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Baillière's Clinical Haematology 7:4, pages 965-1000.
Crossref
Crossref
Ali El-Jammal & Douglas M. Templeton. (1994) Reversed-phase high-performance liquid chromatography of non-transferrin-bound iron and some hydroxypyridone and hydroxypyrone chelators. Journal of Chromatography B: Biomedical Sciences and Applications 658:1, pages 121-127.
Crossref
Crossref
E.W. Randell, J.G. Parkes, N.F. Olivieri & D.M. Templeton. (1994) Uptake of non-transferrin-bound iron by both reductive and nonreductive processes is modulated by intracellular iron.. Journal of Biological Chemistry 269:23, pages 16046-16053.
Crossref
Crossref
Karen O. Hamilton, Lorraine Stallibrass, Ian Hassan, Yi Jin, Christine Halleux & Martin Mackay. (2008) The transport of two iron chelators, desferrioxamine B and L1, across Caco‐2 monolayers. British Journal of Haematology 86:4, pages 851-857.
Crossref
Crossref
Plácido Navas, JoséM. Villalba & Francisco Córdoba. (1994) Ascorbate function at the plasma membrane. Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes 1197:1, pages 1-13.
Crossref
Crossref
Samar Rachidi, Charles Coudray, Paul Baret, Gisèle Gelon, Jean-Louis Pierre & Alain Favier. (1994) Inhibition of lipid peroxidation by a new family of iron chelators. Biological Trace Element Research 41:1-2, pages 77-87.
Crossref
Crossref
A. Yu. Meshchanov, G. N. Kol'tsova, L. T. Minina, V. A. Gorodkova, I. V. Smirnov & V. N. Bovenko. (1994) Biodegradable polymeric hydroxamic acids for the elimination of iron from the body. Pharmaceutical Chemistry Journal 28:3, pages 173-176.
Crossref
Crossref
S. D. Lytton, M. Loyevsky, J. Libman, B. Mester, A. Shanzer & Z. Ioav Cabantchik. 1994. Progress in Iron Research. Progress in Iron Research
385
397
.
Simon D. Lytton, Mark Loyevsky, Brenda Mester, Jacqueline Libman, Irene Landau, Abraham Shanzer & Z. Ioav Cabantchik. (2006)
In vivo antimalarial action of a lipophilic iron (III) chelator: Suppression of
plasmodium vinckei
infection by reversed siderophore
. American Journal of Hematology 43:3, pages 217-220.
Crossref
Crossref
Marco Soriani, Silvia Mazzuca, Valentina Quaresima & Maurizio Minetti. (1993) Oxidation of deseferrioxamine to nitroxide free radical by activated human neutrophils. Free Radical Biology and Medicine 14:6, pages 589-599.
Crossref
Crossref
Chaim Hershko. (1993) Development of oral iron chelator L1. The Lancet 341:8852, pages 1088-1089.
Crossref
Crossref
Youssef G. Comair, Hyman M. Schipper & Steven Brem. (1993) The Prevention of Oxyhemoglobin-Induced Endothelial and Smooth Muscle Cytoskeletal Injury by Deferoxamine. Neurosurgery 32:1, pages 58-65.
Crossref
Crossref
Youssef G. Comair, Hyman M. Schipper & Steven Brem. (1993) The Prevention of Oxyhemoglobin-Induced Endothelial and Smooth Muscle Cytoskeletal Injury by Deferoxamine. Neurosurgery 32:1, pages 58???65.
Crossref
Crossref
M. Fontecave & J.L. Pierre. (1993) Iron: Metabolism, toxicity and therapy. Biochimie 75:9, pages 767-773.
Crossref
Crossref
M. Struck, P. Waldmeier & V. Berdoukas. 1993. Iron in Central Nervous System Disorders. Iron in Central Nervous System Disorders
189
196
.
. (2008) Abstracts of the State of the Art Symposia Presented at the 24th Congress of the International Society of Haematology, London, 23–27 August 1992. British Journal of Haematology 82:1, pages 181-271.
Crossref
Crossref
Lidija Stuhne-Sekalec, Sonny X. Xu, Joel G. Parkes, Nancy F. Olivieri & Douglas M. Templeton. (1992) Speciation of tissue and cellular iron with on-line detection by inductively coupled plasma-mass spectrometry. Analytical Biochemistry 205:2, pages 278-284.
Crossref
Crossref
E. Baker, A. Wong, H. Peter & A. Jacobs. (2008)
Desferrithiocin is an effective iron chelator
in vivo
and
in vitro
but ferrithiocin is toxic
. British Journal of Haematology 81:3, pages 424-431.
Crossref
Crossref
Michael Shannon, Veronika Macarol, ShantaramJ. Yawalkar, K.W. Chan, M. Bond, W. Fernandez, K.J. Anderson, R.P.A. Rivers, Lawrence Helson, Christians Helson, Susan Braverman, Giovanni Deb & Alberto Donfrancesco. (1992) Desferrioxamine in acute iron poisoning. The Lancet 339:8809, pages 1601-1603.
Crossref
Crossref
Erica Baker, Des Richardson, Sharon Gross & Prem Ponka. (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:3, pages 492-501.
Crossref
Crossref
Chaim Hershko. (1992) Iron chelators in medicine. Molecular Aspects of Medicine 13:2, pages 113-165.
Crossref
Crossref
S. Kamchonwongpaisan, N. Vanitchareon & Y. Yuthavong. 1992. Lipid-Soluble Antioxidants: Biochemistry and Clinical Applications. Lipid-Soluble Antioxidants: Biochemistry and Clinical Applications
363
372
.
Lukas C. Kühn. (2008) mRNA‐PROTEIN INTERACTIONS REGULATE CRITICAL PATHWAYS IN CELLULAR IRON METABOLISM. British Journal of Haematology 79:1, pages 1-5.
Crossref
Crossref
G. Lucarelli. (1991) FOR DEBATE: BONE MARROW TRANSPLANTATION FOR SEVERE THALASSAEMIA (1) THE VIEW FROM PESARO. British Journal of Haematology 78:3, pages 300-303.
Crossref
Crossref
Y. Bentur, P.St. Louis, J. Klein & G. Koren. (1991) Misinterpretation of iron-binding capacity in the presence of deferoxamine. The Journal of Pediatrics 118:1, pages 139-142.
Crossref
Crossref
NANCY F. OLIVIERI, DOUGLAS M. TEMPLETON, GIDEON KOREN, DEREK CHUNG, CHRISTINE HERMANN, MELVIN H. FREEDMAN & ROBERT A. McCLELLAND. (1990) Evaluation of the Oral Iron Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one (L1) in Iron-Loaded Patients. Annals of the New York Academy of Sciences 612:1 Sixth Cooley', pages 369-377.
Crossref
Crossref
PHILIP AISEN, GERALD COHEN & JAE O. KANG. 1990. Transition Metal Toxicity. Transition Metal Toxicity
1
46
.